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Background/Aims: Prognostic models are lacking for pa-
tients with recurrent hepatocellular carcinoma (HCC) follow-
ing surgical resection. This study devised and validated a 
new hepatoma arterial-embolization prognostic (HAP) score 
optimized for use in patients undergoing treatment with tran-
sarterial chemoembolization (TACE) for recurrence subse-
quent to surgical resection of HCC. Methods: Training cohort 
(n=424) and validation cohort (n=350) patients with recur-
rent HCC after resection treated with TACE between 2003 
and 2016 were enrolled. Cox regression and area under 
the receiver operating characteristic curve (AUC) analyses 
were used to identify risk factors for survival and to calcu-
late the predictive performance of risk scores, respectively. 
Results: The median age of the study population was 59.2 
years. α-Fetoprotein >400 ng/mL (hazard ratio [HR]=1.815), 
serum albumin ≤3.5 g/dL (HR=1.966), tumor number ≥2 
(HR=1.425), tumor size >5 cm at resection or recurrence 
(HR=1.356), segmental portal vein invasion at resection or 
recurrence (HR=2.032), and time from resection to recur-
rence ≤1 years (HR=1.849) independently predicted survival 
(all p<0.05). The postoperative HAP (pHAP) model based on 
the rounded HRs of these variables showed an AUC of 0.723 
for predicting survival at 3 years, which was significantly 
higher than AUCs of other HAP-based models, including HAP, 
modified HAP, and modified HAP-II scores (0.578-0.621) (all 
p<0.05). The accuracy of pHAP was maintained in the entire 
cohort (n=774; AUC=0.776 at 3 years). Conclusions: A new 
pHAP score optimized for patients treated with TACE due to 
recurrent HCC after resection showed acceptable accuracy 
and was externally validated. Further studies of means by 
which to select treatment options other than TACE for high-
risk patients according to pHAP scores are warranted. (Gut 
Liver 2020;14:477-485 )
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a common cancer, and 
the third most common cause of cancer-associated death.1 With 
active surveillance programs supporting the detection of early 
stage HCC, the number of patients eligible for surgical treatment 
for HCC has increased.1-3 Although improvements in surgical 
techniques3,4 and adequate selection criteria for resection have 
led to significant gains in survival and reductions in postopera-
tive morbidity and mortality, the long-term prognosis remains 
unsatisfactory owing to the recurrence of HCC despite surgical 
resection.5
Among the many treatment options for HCC that recurs fol-
lowing surgical resection, transarterial chemoembolization 
(TACE) has been shown to offer survival advantages in several 
randomized trials and a subsequent systematic review.6-9 Ac-
cordingly, TACE might be of use in treating recurrent HCC of 
Barcelona Clinic Liver Cancer (BCLC) intermediate stage B or 
early stage HCC not indicated for other curative treatments.10 
However, it can be postulated that survival might vary greatly 
after TACE treatment for recurrent HCC due to variances in liver 
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function and tumor burden upon HCC recurrence and the length 
of time till recurrence after surgical resection.11 Thus, it is of 
paramount importance to select candidates who would benefit 
most from TACE for recurrent HCC after surgical resection.
Recently, hepatoma arterial-embolization prognostic (HAP) 
score, which is composed of four variables, including α-fetopro-
tein (AFP), tumor size, serum albumin, and total bilirubin, has 
been shown to predict outcomes following TACE.12 In addition, 
two adjusted versions of the HAP score have also been sug-
gested: the modified HAP (mHAP) score, which excludes total 
bilirubin from the HAP score,13 and the mHAP-II score, which 
adds tumor number as one of the constituent variables.14 How-
ever, it is not known whether these risk scores show acceptable 
accuracy when applied to patients with recurrent HCC after sur-
gical resection.
Thus, in this multicenter, retrospective study, we aimed to es-
tablish a new postoperative HAP (pHAP) score optimized for use 
in patients treated with TACE due to recurrent HCC following 
surgical resection and to validate the score externally. In addi-
tion, we compared the prognostic accuracy of the new model to 
the prognostic accuracy of existing HAP-related risk scores in 
the present study cohort. 
MATERIALS AND METHODS
1. Patient eligibility
In this retrospective multicenter cohort study, we included 
consecutive patients undergoing treatment with TACE for recur-
rence subsequent to surgical resection of HCC between 2003 
and 2015 (n=424 for the training cohort, Severance Hospital, 
Yonsei University College of Medicine) and 2003 to 2016 (n=350 
for the validation cohort, Seoul National University Hospital, 
Seoul National University College of Medicine). The institutions 
in our study had extensive experience in the treatment of HCC 
using TACE.
Study exclusion criteria were (1) treatment modality other 
than TACE as first-line therapy; (2) inadequate target lesions on 
radiological assessment (non-arterial enhancement or largest le-
sion <1 cm); (3) presence of an additional primary malignancy 
in another organ; (4) presence of extrahepatic tumor lesions; (5) 
presence of tumor invasion to the main portal vein; (6) history 
of liver transplantation; (7) other serious medical comorbidities 
that might affect survival; (8) Child-Pugh class C; (8) BCLC stage 
D; and (9) a follow-up duration <6 months (Fig. 1).
The study protocol was in accordance with the Declaration of 
Helsinki guidelines and was approved by the Institutional Re-
view Boards of Severance Hospital and Seoul National Univer-
sity Hospital. Due to retrospective nature of this study, the need 
for informed consent from the participants was waived.
2. Diagnosis and staging of HCC
HCC was diagnosed in accordance with the guidelines pro-
posed by the Korea Liver Cancer Study Group.15 Typical HCC 
findings on dynamic computed tomography or magnetic reso-
nance imaging were increased arterial enhancement and de-
creased enhancement.15,16 The BCLC staging system was applied 
for tumor staging, as previously described.17
3. TACE procedure and follow-up
Prior to the TACE procedure, angiography was utilized to 
assess vascular anatomy, patency, and tumor vascularity.14 
Conventional TACE was performed using a selective infusion 
of a mixture of 5 mL of iodized oil contrast medium (Lipiodol®; 
Guerbet LLC, Bloomington, IN, USA) and either 50 mg of doxo-
rubicin or cisplatin at 2 mg/kg body weight, followed by em-
bolization using gelatin sponge particles (Cutanplast®; Mascia 
Brunelli Spa, Milan, Italy). Radiologic responses to TACE were 
defined based on the modified Response Evaluation Criteria in 
1,306 Patients with HCC who underwent curative
resection between 2003 and 2015
607 Patients with recurred HCC
424 Patients treated with TACE
Other treatment modality except TACE
Inadequate target lesions on radiologic assessment
Presence of additional malignancies in another organ
Presence of extrahepatic tumor lesions
Presence of tumor invasion to the main portal vein
Presence of liver transplantation history
Other serious medical comorbidities that might affect the survival
Child-Pugh classification C
BCLC stage D
Duration of follow-up <6 months
Fig. 1. Study population flowchart. A total of 1,306 patients with hepatocellular carcinoma (HCC) who underwent curative resection between 
2003 and 2015 were placed in our training cohort. After the application of exclusion criteria, the training cohort consisted of 424 patients who 
underwent transarterial chemoembolization (TACE) due to recurrent HCC following curative resection (Yonsei University). Similarly, the validation 
cohort consisted of 350 patients with HCC who underwent curative resection between 2003 and 2016 and were treated with TACE due to recur-
rent HCC (Seoul National University).
BCLC, Barcelona Clinic Liver Cancer.
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Solid Tumours on computed tomography or magnetic resonance 
imaging.18 TACE was repeated at 6- to 8-week intervals on an 
“on-demand” until achievement of a complete response.18
4. Study design
This study was conducted in four parts. First, we attempted 
to identify variables associated with survival following TACE 
for recurrent HCC after surgical resection in the training cohort. 
Second, we estimated the accuracy of HAP-based risk models 
(Supplementary Table 1) to predict survival after TACE in the 
training set. Third, we established a new risk model optimized 
for patients in the study who experienced recurrence of HCC 
despite surgical resection and calculated the accuracy of the 
model, which was compared with the accuracy of other HAP-
related risk models. Lastly, the accuracy of the new risk model 
was validated in the validation set.
5. Statistical analysis
Patient and tumor characteristics at baseline are presented as 
a median (interquartile range) or number (%) as appropriate. The 
Mann-Whitney test and Fisher exact test were used to compare 
characteristics between the study institutes, as appropriate. Sur-
vival and differences therein were analyzed using the Kaplan-
Meier method and log-rank test.
The influence of variables on survival was evaluated using 
univariate and multivariate Cox regression analyses. The pre-
dictive performances of HAP-related risk scores and the newly 
established risk score at the time of TACE were assessed using 
area under the receiver operating characteristic curves (AUCs) to 
predict mortality at 1-, 3- and 5-year follow-up. The AUCs were 
compared using the DeLong test.
To compare the homogeneity and discriminatory ability of 
HAP-related risk scores and the newly established risk score, 
the likelihood ratio test and the linear trend test were utilized. 
In addition, the Akaike information criteria were calculated to 
demonstrate which of the risk scores was more explanatory and 
informative for risk assessment for survival among the existing 
HAP-related risk scores and the newly established one (smaller 
Akaike information criteria indicates preferred risk score).
All p-values <0.05 were considered indicative of statistical sig-
nificance. The statistical analyses were conducted using SPSS 23.0 
for Windows (IBM Corp., Armonk, NY, USA) and MedCalc Soft-
ware version 12.7.2 (MedCalc Software bvba, Ostend, Belgium).
RESULTS
1. Baseline characteristics
A flowchart describing selection of the study population 
is shown in Fig. 1. Between 2003 and 2015, a total of 1,306 
patients with HCC underwent surgical resection. Of these, 424 
patients underwent TACE due to recurrent HCC after surgical 
resection and were include in the training cohort. Similarly, the 
validation cohort consisted of 350 patients with HCC who re-
ceived surgical resection between 2003 and 2016 and TACE due 
to recurrent HCC.
Baseline data doe the training cohort at the time of TACE are 
shown in Table 1. The median age was 59.2 years (interquartile 
Table 1. Baseline Characteristics of the Patients at the Time of TACE 
due to Recurrent HCC after Curative Resection (Training Set, n=424)
Variable Value
Demographic variable
   Age, yr 59.2 (52.2–66.6)
   Male sex 359 (84.7)
   Etiology 
      HBV 345 (81.4)
      HCV 36 (8.5)
      Others 43 (10.1)
   Child-Pugh class
      A 415 (97.9)
      B 9 (2.1)
   BCLC stage
      0 133 (31.4) 
      A 163 (38.4) 
      B 103 (24.3)
      C 25 (5.9)
Laboratory variables
   α-Fetoprotein, ng/mL 7.5 (3.0–75.5)
   Total bilirubin, mg/dL 0.8 (0.6–1.0)
   Serum albumin, g/dL 4.0 (3.7–4.3)
Tumor variables 
   Tumor size, cm
      ≤7/>7 414 (97.6)/10 (2.4)
      ≤5/>5 409 (96.5)/15 (3.5)
   Tumor number
      Unifocal 229 (54.0)
      Multifocal 195 (46.0)
   Segmental portal vein invasion 25 (5.9)
Tumor variables at the time of resection
   Tumor size, cm
      ≤7/>7 381 (89.9)/43 (10.1)
      ≤5/>5 313 (73.8)/111 (26.2)
   Tumor number
      Unifocal 354 (83.5)
      Multifocal 70 (16.5)
   Segmental portal vein invasion 32 (7.5)
Time from resection to recurrence, mo 17.7 (7.2–36.6)
Data are presented as the median (interquartile range) or number (%).
TACE, transarterial chemoembolization; HCC, hepatocellular carcino-
ma; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona 
Clinic Liver Cancer.
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range, 52.2–66.6 years) and 359 patients (84.7%) were men. 
The most common etiology of HCC was hepatitis B virus (HBV) 
infection (n=345, 81.4%). A total of 415 patients (97.9%) had 
well-preserved liver function (Child-Pugh class A), and 296 
patients (69.8%) were BCLC stage 0–A. Data for the validation 
cohort are shown in Supplementary Table 2. The comparisons 
among patients according to period of recurrence of HCC after 
resection (≤1 or >1 year) in the training cohort were described 
in Supplementary Table 3. Age, BCLC stage, AFP, serum albu-
min, tumor size >7 cm, tumor number at the time of recurrence 
and tumor size >5 cm at the time of resection demonstrated 
significant differences between patients with recurrences within 
and more than 1-year of surgical resection (all p<0.05). 
2. Survival after TACE due to recurred HCC and its risk fac-
tors
The survival rates at 1, 3, and 5 years after TACE, respec-
tively, were 87.4%, 62.6%, and 47.8%, and the median survival 
was 57.1 months (interquartile range, 41.4–72.8 months) in the 
training cohort.
Table 2. Univariate Cox Regression Analysis to Identify Potential Risk Factors for Overall Mortality at the Time of TACE after Curative Resection 
(Training Set, n=424)
Variable HR (95% CI) p-value
Age 0.991 (0.979–1.003) 0.123
Male (n=359) (vs female, n=65) 1.105 (0.778–1.570) 0.577
Viral etiology (n=381) (vs non-viral, n=43) 1.128 (0.733–1.735) 0.584
α-Fetoprotein, ng/mL
   >400 (n=44) (vs ≤400, n=380) 2.050 (1.425–2.949) <0.001
Total bilirubin, mg/dL
   >1.7 (n=10) (vs ≤1.7, n=414) 1.054 (0.468–2.371) 0.899
Serum albumin, g/dL
   ≤3.5 (n=57) (vs >3.5, n=367) 2.012 (1.445–2.801) <0.001
Tumor variable
   Tumor size, cm
      >5 (n=15) (vs ≤5, n=409) 2.459 (1.400–4.320) 0.002
   Multifocal (n=70) (vs unifocal, n=354) 1.574 (1.220–2.030) <0.001
   Segmental portal vein invasion (n=25) 2.925 (1.820–4.702) <0.001
Tumor variables at the time of resection
   Tumor size, cm
      >5 (n=111) (vs ≤5, n=313) 1.345 (1.018–1.775) 0.037
   Multifocal (n=70) (vs unifocal, n=354) 1.099 (0.779–1.547) 0.592
   Segmental portal vein invasion (n=32) 1.845 (1.208–2.817) 0.005
   Time from resection to recurrence, yr
      ≤1 (n=159) (vs >1, n=265) 2.361 (1.829–3.047) <0.001
TACE, transarterial chemoembolization; HR, hazard ratio; CI, confidence interval.
Table 3. Multivariate Cox Regression Analysis to Identify Independent Risk Factors for Poor Survival and the Corresponding Rounded Risk Score 
Based on pHAP Score (Training Set, n=424)
Variable
Multivariate Allocation of rounded 
score for pHAP scoreHR (95% CI) p-value
α-Fetoprotein (>400 ng/mL) 1.815 (1.242–2.651) 0.002 1
Serum albumin (≤3.5 g/dL) 1.966 (1.401–2.760) <0.001 1
Tumor number at the time of recurrence (≥2) 1.425 (1.093–1.859) <0.001 1
Tumor size (>5 cm) at the time of resection or recurrence 1.356 (1.028–1.789) 0.031 1
Segmental PVI at the time of resection or recurrence 2.032 (1.436–2.875) <0.001 1
Time from resection to recurrence (≤1 yr) 1.849 (1.412–2.422) <0.001 1
Risk group are classified into pHAP A (0-1 point), pHAP B (2 points), pHAP C (3 points), or pHAP D (≥ 4 points), respectively.
pHAP, postoperative hepatoma arterial-embolization prognostic; HR, hazard ratio; CI, confidence interval; PVI, portal vein invasion.
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On univariate analyses, AFP level >400 ng/mL, serum albu-
min level ≤3.5 g/dL, multifocal tumor at the time of recurrence, 
tumor size >5 cm and segmental portal vein invasion at the 
time of resection or recurrence, and time from resection to re-
currence were risk factors for poor survival (all p<0.05) (Table 2). 
Subsequent multivariate analysis identified AFP level >400 ng/
mL, serum albumin level ≤3.5 g/dL, multiple tumors at the time 
of recurrence, tumor size >5 cm at the time of resection or re-
currence, segmental portal vein invasion at the time of resection 
or recurrence, and time from resection to recurrence ≤1 years as 
independent risk factors for poor survival (Table 3). 
Using these variables, we developed our pHAP model for 
patients treated with TACE due to recurrent HCC after surgical 
resection was developed and validated (Supplementary Tables 4 
and 5). The pHAP score was defined as the sum of the points of 
the six variables, and patients were classified into pHAP A (0–1 
point), pHAP B (2 points), pHAP C (3 points), or pHAP D (≥4 
points), respectively (Table 3).
3. Predictive performance of pHAP and other HAP-related 
risk scores
The AUC values of pHAP and other HAP-related risk scores 
were calculated and compared (Table 4). The AUC values of 
pHAP score were 0.799 at 1 year, 0.723 at 3 years, and 0.697 at 
5 years (all p<0.001). Comparison of the AUC values, revealed 
a significantly higher AUC for pHAP score than for the other 
HAP-related risk scores from 1 to 5 years (AUC: 0.697–0.799 
for pHAP vs 0.565–0.682 for HAP, 0.567–0.681 for mHAP, and 
0.618–0.728 for mHAP-II) (all p<0.05). Similar AUC values were 
identified in the entire cohort including the training and valida-
tion cohorts (0.812 at 1 year, 0.776 at 3 years, and 0.768 at 5 
years) (Supplementary Table 6).
4. Survival outcomes according to pHAP and other HAP-
related risk scores
Median survival and survival rates at 1 to 5 years in the 
training cohort are presented in Supplementary Table 7 accord-
ing to pHAP and other HAP-related risk scores. Kaplan-Meier 
survival curves for each of the risk groups in the pHAP score 
model are depicted in Fig. 2. The survival curves of four risk 
groups based on pHAP score were significantly different (overall 
log-rank, p<0.001). Similar to the results observed in the train-
ing cohort, the survival curves of the four risk groups based on 
pHAP and the other HAP-related risk scores in the validation 
cohort and the entire cohort were significantly different (overall 
all p<0.001 by log-rank test) (Supplementary Fig. 1).
5. Prognostic accuracy of pHAP and other HAP-related risk 
scores
Among the risk scores, pHAP score showed the highest ho-
mogeneity compared to the other HAP-related risk scores (likeli-
hood ratio, 87.501 vs 32.207 to 46.437), the highest discrimina-
tory ability (linear trend, 81.932 vs 30.977 to 45.583), and the 
lowest Akaike information criteria value (2,536.533 vs 2,560.487 
to 2,576.985), indicating the best prognostic performance in pa-
tients treated with TACE due to recurrent HCC after surgical re-
section (Table 5). When these were applied to the entire cohort, 
similar results were observed (Supplementary Table 8).
DISCUSSION
Recent randomized controlled trials and meta-analyses have 
Table 4. Predictive Performance of HAP, mHAP-I, mHAP-II, and pHAP (n=424 in Training, n=350 in Validation)
Follow-up
Training cohort
HAP mHAP mHAP-II pHAP
AUC (95% CI) p-value‡ AUC (95% CI) p-value‡ AUC (95% CI) p-value‡ AUC (95% CI)
Entire 
   1 Year 0.682 







   2 Years 0.617 







   3 Years 0.578 







   4 Years 0.579 







   5 Years 0.565 







HAP, hepatoma arterial-embolization prognostic; mHAP, modified HAP; pHAP, postoperative HAP; AUC, area under the receiver operating char-
acteristic curve; CI, confidence interval.
*p<0.001; †p<0.05; ‡p-value indicates a significant AUC for pHAP in the training set by the DeLong test.
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proven that TACE can provide survival benefit in patients with 
unresectable HCC.19 However, due to heterogeneity in liver 
function and tumor characteristics at the time of TACE, as well 
as individual differences regarding the performance of TACE 
among institutions,20 a wide-range of treatment outcomes has 
been reported.21 Thus, it has been important to distinguish pa-
tients who would benefit from TACE from those who would 
not and should hence receive alternative treatments, such as 
sorafenib or other palliative treatments.22,23
Although several previous studies have compared the ability 
of various staging systems to predict the survival in patients 
with unresectable HCC treated with TACE,24,25 several simple-to-
use risk stratification models, such as the HAP model12 and its 
modifications,13,14,22 have also been proposed. However, because 
no risk stratification model for TACE due to recurrent HCC after 
surgical resection has been available, our study aimed to iden-
tify independent risk factors for poor survival in this clinical 
setting and to develop and validate a new risk model. In this 
study, our new risk model, pHAP, demonstrated an AUC to pre-
dict survival at 3 years of 0.723, significantly higher than AUCs 
of other HAP-based models (AUC, 0.578 to 0.621) (all p<0.05 
between AUCs).
Our study has several strengths. First is the large sample size 
(n=774) and the long-term follow-up period (median 57.1, up to 
155.9 months). This gave us greater statistical power with which 
to identify prognostic factors for poor long-term prognosis and 
to establish a score model optimized for patients who undergo-
ing TACE due to recurrent HCC after surgical resection. To the 
best of our knowledge, this study is the first to identify such 
prognostic factors, to establish a new predictive model (pHAP 
model), to achieve external validation thereof, and to demon-
strate the superior predictive accuracy of the model with high 
homogeneity and discriminatory ability, compared to those of 
HAP and its modifications, in this clinical setting. Moreover, the 
pHAP model-maintained simplicity in score calculation, a fea-
ture that might be helpful for clinicians in use of the model in 
clinical practice.
Second, as the intense surveillance strategy with computed 
tomography or magnetic resonance imaging to detect recurrence 
is significantly different from the ultrasound-based surveillance 
for CHB-patients without HCC, a different risk stratification sys-
tem is strongly required for patients who underwent TACE due 
to recurrent HCC after resection. Re-resection is generally in-
feasible in patients who have already undergone surgery due to 
technical difficulties, although these patients might have well-
preserved liver function with early stage recurrent HCC as a re-
sult of intensive follow-up. In comparison to previous studies of 
HAP and its modifications,12-14 the proportion of single tumors 
(54.0% vs 37% to 42%) and small diameter of tumor size (≤7 
cm) (97.6% vs 70% to 86%) were higher and the median AFP 
level was lower (7.7% vs 15% to 28%) in patients treated with 
TACE after resection. For these reasons, despite post-resection 
status, the median overall survival after the initial TACE in our 
cohort was significantly longer at 43.3 months, compared to 
Table 5. Prognostic Accuracy of Risk Scores during TACE to Predict 







HAP 32.207 30.977 2,576.985
mHAP 41.077 39.273 2,567.679
mHAP-II 46.437 45.583 2,560.487
pHAP 87.501 81.932 2,536.533
The model with a higher χ2 value by the likelihood ratio and linear 
trend tests was considered the better model for homogeneity and dis-
criminatory ability. Furthermore, lower values for the Akaike infor-
mation criteria (AIC) were considered to indicate better discriminatory 
ability.
TACE, transarterial chemoembolization; HAP, hepatoma arterial-
embolization prognostic; mHAP, modified HAP; pHAP, postoperative 
HAP.
Fig. 2. Cumulative overall survival rate according to pHAP stratification (Kaplan-Meier curves). (A) Cumulative survival curves in the training set 
(overall, p<0.001; A vs B class, p=0.007; A vs C class, p<0.001; A vs D class, p<0.001; all by log-rank test), (B) the validation set (overall, p<0.001; 
A vs B class, p<0.001; A vs C class, p<0.001; A vs D class, p<0.001; all by log-rank test), and (C) the entire cohort (overall, p<0.001; A vs B class, 
p<0.001; B vs C class, p<0.001; A vs D class, p<0.001; all by log-rank test).
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13.7–36.2 months in previous studies in which HAP and its 
modifications were derived.12,13 This difference is the main rea-
son why we tried to focus on the patients who underwent TACE 
due to recurrent HCC after surgical resection. However, because 
our cohort included patients treated with TACE after resection 
despite very early and early HCC stage, the results should be in-
terpreted with caution.
Third, in contrast to previous studies proposing HAP mod-
els,12-14 total bilirubin level lacked predictive ability for survival. 
This finding can be partly explained based on the selection of 
our study population cohort. Because our cohort with recur-
rent HCC consisted of only patients who could endure previous 
surgical resection, well-preserved liver function might be main-
tained at the time of TACE due to recurrent HCC. Indeed, the 
proportion of patients with Child-Pugh class A liver function 
in our cohort was higher than those of previous studies (97.9% 
vs 71% to 78%).12,13 In addition, segmental portal vein invasion 
was selected as one of the independent predictors of poor prog-
nosis. In Asian countries, segmental portal vein invasion has not 
been considered a contraindication for TACE.26 Indeed, the pro-
portion of segmental portal vein invasion at TACE has not been 
reported negligible in previous studies.12,14 Thus, incorporation 
of segmental portal vein invasion into the pHAP model might 
be generally applicable. In addition, a shorter time interval from 
resection to TACE (<1 year) was an independent poor prognos-
tic factor. The selection of this variable can be easily supported 
by considering that the early recurrence of HCC after resection 
has been reported to be a prognostic factor for survival despite 
treatment,27 which in turn supports our rationale to develop a 
risk prediction model for recurrent HCC after resection that in-
cludes the time interval between TACE and resection as one of 
the constituent variables.
Our study also has several limitations. First, our study popu-
lation consisted of Korean patients only, the majority of whom 
had HBV as the etiology for HCC (around 80%). Therefore, vali-
dation of our findings in other ethnic populations with varying 
etiologies for HCC is strongly required. In addition, we retro-
spectively selected only patients who underwent TACE due to 
recurrence. However, the decision of whether to perform TACE 
or not can be significantly influenced by previous treatment 
modality, tumor number, and location and size of tumor, creat-
ing a possible selection bias. We attempted to overcome this 
potential bias by validating the pHAP model in a large-sized 
external cohort (n=350) and demonstrating the applicability 
of the pHAP model in patients undergoing TACE after resec-
tion. Second, the overall diagnostic accuracy is not that high 
in contrast to those observed in previous studies of HAP and 
its modifications. Although the exact reason for these findings 
is not clear, this phenomenon can be explained in part by the 
selection of variables at the time of recurrence. Furthermore, 
potent antiviral therapy using nucleotide analogues for hepatitis 
B and direct-acting antivirals for hepatitis C might also have an 
impact on the overall survival of our cohort; a possibility that 
should be further investigated in future studies. Third, inter-
institutional variability regarding technical issue and subjective 
decisions regarding treatment might have influenced our final 
results. However, we attempted to validate the pHAP model in 
an external cohort and observed similar diagnostic accuracy 
between the training and validation cohorts. Lastly, although 
re-treatment strategies for TACE have been proposed, such as 
sequential use of various risk models of HAP and its modifica-
tions, ART (Assessment for Retreatment with TACE) score, SNA-
COR (tumor size and number, baseline AFP, Child-Pugh and 
objec tive radiological response), and ABCR score,28-30 the present 
study focused on selection of the optimal candidates for starting 
TACE as the first-line anticancer therapy for recurrent HCC.
In conclusion, we developed and externally validated a new 
HAP model (pHAP) with greater accuracy in patients treated 
with TACE due to the recurrent HCC following surgical resec-
tion. Further studies should investigate appropriate methods 
for selection of treatment options other than TACE for patients 
considered to be at high-risk according to pHAP score.
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